

RSC Drug Discovery

Edited by Patrick M. Woster and Robert A. Casero, Jr.

Polyamine Drug Discovery



RSC Publishing

Polyamine Drug Discovery

Edited by

Patrick M. Woster

Medical University of South Carolina, Charleston, SC, USA

Robert A. Casero, Jr.

John Hopkins University, Baltimore, MD, USA



RSC Publishing

RSC Drug Discovery Series No. 17

ISBN: 978-1-84973-190-4

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© Royal Society of Chemistry 2012

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Polyamine Drug Discovery

RSC Drug Discovery Series

Editor-in-Chief:

Professor David Thurston, *London School of Pharmacy, UK*

Series Editors:

Dr David Fox, *Pfizer Global Research and Development, Sandwich, UK*

Professor Salvatore Guccione, *University of Catania, Italy*

Professor Ana Martinez, *Instituto de Química Medica-CSIC, Spain*

Dr David Rotella, *Montclair State University, USA*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies
- 4: Accounts in Drug Discovery: Case Studies in Medicinal Chemistry
- 5: New Frontiers in Chemical Biology: Enabling Drug Discovery
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration: Metallostatics and Proteostasis
- 8: G Protein-Coupled Receptors: From Structure to Function
- 9: Pharmaceutical Process Development: Current Chemical and Engineering Challenges
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology: Current Status and Application
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247, Email: books@rsc.org

Visit our website at <http://www.rsc.org/Shop/Books/>

Preface

There have been many significant advances in polyamine research since the field was brought to the forefront of biological and biomedical research in the 1970s. Many of the significant findings since that time, whether in plant research, cell biology, the development of therapeutics, genetics or another related field, have been aided by the availability of synthetic compounds specifically designed to inhibit enzymes in the polyamine pathway or otherwise disrupt polyamine metabolism. For example, a search of PubMed using the terms difluoromethylornithine AND dfmo AND eflornithine produces 1179 references dating to 1980, and including research in diverse areas such as plant biochemistry, cancer cell biology, parasitology, insect biochemistry, synthetic chemistry, drug development and human clinical trials. Despite the diversity of fields of endeavor within polyamine research and the significant impact of modulators of polyamine metabolism, a book dedicated to the discovery and development of synthetic compounds targeting polyamine metabolism as drugs has never been produced. The purpose of this book is to fill that void by presenting an overview of drug-discovery research within the polyamine field.

The impetus for a significant portion of polyamine research has been provided by the availability of synthetic analogs that produce defined effects on polyamine metabolism *in vitro* and *in vivo*. This book begins with a chapter that outlines the synthetic approaches to these analogs, covering areas such as nucleotide synthesis and synthetic routes used to access various polyamine analogs. The structural biology aspects of polyamine drug discovery are detailed, as are efforts to design and discover specific inhibitors of enzymes in the polyamine pathway. Chapters are also included that address the role of polyamine analogs as antiparasitic agents, antineoplastic agents and epigenetic modulators. In addition, the important role played by polyamine oxidation is detailed. Other important areas within polyamine drug discovery research, such

RSC Drug Discovery Series No. 17

Polyamine Drug Discovery

Edited by Patrick M. Woster and Robert A. Casero, Jr.

© Royal Society of Chemistry 2012

Published by the Royal Society of Chemistry, www.rsc.org

as polyamine transport, the development of polyamine–metal complexes as antitumor agents and the design of polyamine-based gene transfer reagents, are discussed. Finally, a chapter is included that describes the promising results from recent human clinical trials involving drugs targeting polyamine metabolism. The result is a broad overview of polyamine drug discovery and the translation of new chemical entities from basic chemistry to studies involving patients.

Those of us who have a long history in polyamine drug discovery research know that it is a cyclic endeavor, with drug discovery successes appearing periodically and clinical successes appearing steadily but infrequently. However, recent clinical research with existing compounds, including DFMO and the bis(ethyl)polyamine analogs PG-11093 and PG-11144, bode well for the future. In particular, DFMO has found utility as a chemopreventative agent in combination with sulindac, and the bis(ethyl)polyamines have produced promising results in combination antitumor studies. Not since the advent of DFMO has the field of polyamine drug discovery research been so close to bringing a drug to market. We hope that after perusing this book, the reader will have gained an appreciation for polyamine drug discovery efforts that are occurring on multiple fronts. We also hope that you will share the confidence inherent in modern polyamine researchers that significant successes in polyamine drug discovery are on the horizon.

Patrick M. Woster
Robert A. Casero, Jr

Contents

Chapter 1	Polyamine Drug Discovery: Synthetic Approaches to Therapeutic Modulators of Polyamine Metabolism	1
	<i>Patrick M. Woster</i>	
1.1	Introduction	1
1.2	Polyamine Metabolism as a Drug Target	2
1.3	Synthetic Approaches to Modulators of Polyamine Metabolism and Function	3
1.3.1	Ornithine Decarboxylase (ODC)	3
1.3.2	S-Adenosylmethionine Decarboxylase (AdoMet-DC)	6
1.3.3	Spermidine Synthase and Spermine Synthase	15
1.3.4	Terminally Alkylated Polyamine Analogs	17
1.3.5	Polyamine-Based Epigenetic Modulators	19
1.4	Conclusion	24
	References	24
Chapter 2	Structural Biology in Polyamine Drug Discovery	28
	<i>Shridhar Bale and Steven E. Ealick</i>	
2.1	Structural Biology and Drug Design	28
2.2	Structural Biology of Polyamine-Related Enzymes	29
2.3	S-Adenosylmethionine Decarboxylase	32
2.4	Early Inhibitors of Human AdoMetDC	34
2.5	Crystal Structure of Human AdoMetDC and Mutants	35
2.6	Inhibitor Design for Active Site of AdoMetDC	37
2.6.1	Role of the Central Nitrogen/Sulfonium Atom	37
2.6.2	Role of the Linker Length and Terminal Group	38
2.6.3	Effect of 8-Substitution	40

RSC Drug Discovery Series No. 17

Polyamine Drug Discovery

Edited by Patrick M. Woster and Robert A. Casero, Jr.

© Royal Society of Chemistry 2012

Published by the Royal Society of Chemistry, www.rsc.org

2.7	Search for New Inhibitors by Virtual Screening	41
2.8	Inhibitor Design for the Putrescine-Binding Site and Proenzyme	41
2.9	Interspecies Correlations	43
2.9.1	Classification of AdoMetDC	43
2.9.2	Ligand Binding in Prokaryotic AdoMetDC	44
2.9.3	Implications of the Prozyme	45
	References	46
Chapter 3	Antiparasitic Drug Discovery for the Polyamine Pathway	50
	<i>Nigel Yarlett and Mary Morada</i>	
3.1	Ornithine Decarboxylase	50
3.2	S-Adenosylmethionine Decarboxylase	53
3.3	Spermidine Synthase	55
3.4	Trypanothione Synthase	57
3.5	Trypanothione Reductase	61
3.5.1	Tricyclics	61
3.5.2	Polyamine Analogs	62
3.5.3	Redox Inhibitors	62
3.5.4	Substrate Analogs	64
3.5.5	Compounds Identified Through Screening of a Library of Drug-Like Compounds	65
3.6	Hypusine	66
3.7	Polyamine Retroconversion Pathways: SSAT/PAO/SMO	68
	References	72
Chapter 4	Inhibitors of Polyamine Biosynthetic Enzymes	78
	<i>Anthony E. Pegg</i>	
4.1	Introduction	78
4.2	Inhibition of ODC	79
4.2.1	α -Difluoromethylornithine (DFMO)	79
4.2.2	Other ODC Inhibitors	83
4.3	Inhibition of AdoMetDC	84
4.3.1	MGBG, SAM686A and Related Compounds	84
4.3.2	AbeAdo and Other AdoMet Derivatives	86
4.3.3	AbeAdo and Other AdoMetDC Inhibitors	87
4.3.4	Therapeutic Potential of AdoMetDC Inhibitors	87
4.4	Inhibition of Aminopropyltransferases	89
4.4.1	Product Inhibition of Aminopropyltransferases	89
4.4.2	SpdSyn Inhibitors	89
4.4.3	SpmSyn Inhibitors	91

4.5	Conclusions	92
	References	93

Chapter 5 Symmetrical- and Unsymmetrical Terminally Alkylated Polyamines **104**

Patrick M. Woster and Robert A. Casero, Jr

5.1	Introduction	104
5.2	Symmetrical, Terminally Alkylated Polyamines	106
5.3	Unsymmetrical, Terminally Alkylated Polyamines	112
5.4	Polyamine Isosteres and Epigenetic Activity	122
5.5	Future Directions	129
	References	129

Chapter 6 Targeting the Polyamine Catabolic Enzymes Spermine Oxidase, N¹-Acetylpolyamine Oxidase and Spermidine/Spermine N¹-Acetyltransferase **135**

Andrew C. Goodwin, Tracy R. Murray-Stewart and Robert A. Casero, Jr

6.1	Introduction	135
6.2	Structure, Mechanism of Action and Function of Polyamine Catabolic Enzymes	136
6.2.1	Spermidine/Spermine N ¹ -Acetyltransferase (SSAT)	136
6.2.2	N ¹ -Acetylpolyamine Oxidase (APAO) and Spermine Oxidase (SMO)	139
6.3	Modulation of SMO, APAO and SSAT as a Therapeutic Strategy	144
6.3.1	Polyamine Catabolic Enzymes as Rational Drug Targets in Parasitic Diseases	144
6.3.2	Cytotoxic Polyamine Analogs as Selective Chemotherapeutic Agents	145
6.4	Inhibition of Polyamine Catabolism as a Therapeutic Approach	147
6.4.1	Role of SMO in Inflammation-Associated Tumorigenesis	147
6.4.2	Polyamine Catabolism in Ischemic Injuries	149
6.4.3	Association of Polyamine Catabolic Enzymes With Other Human Diseases	149
6.5	Conclusions	150
	References	150

Chapter 7	Design of Polyamine Transport Inhibitors as Therapeutics	162
	<i>Otto Phanstiel IV and Jennifer Julian Archer</i>	
7.1	Introduction	162
7.2	Models of Polyamine Transport	163
	7.2.1 Homeostasis, Antizyme and Polyamine Transport	164
7.3	Transportons and Anti-Transportons, New Words and Definitions	165
7.4	Role of Polyamine Transportons	166
7.5	Anti-Transportons	167
	7.5.1 Polypyridinium Quaternary Salts	167
	7.5.2 Irreversible and Sulfur-Containing PAT Inhibitors	169
	7.5.3 Dimeric Branched Polyamine Motifs	170
	7.5.4 Acridinyl Linear Polyamine Conjugates	171
	7.5.5 Aryl-Based Anti-Transportons	172
	7.5.6 Trimeric Polyamine Scaffolds	174
	7.5.7 Polyamine–Glutaraldehyde Polymers	174
	7.5.8 Linear Spermine–Amide Dimers	177
	7.5.9 Amino Acid–Spermine Conjugates	177
	7.5.10 Heparin Sulfate (HS)-Binding Agents	181
	7.5.11 Lipophilic Polyamine Conjugates	182
7.6	Conclusions	187
	References	187
Chapter 8	Non-Covalent Polynuclear Platinum Compounds as Polyamine Analogs	191
	<i>Yun Qu, Joseph J. Moniodis, Amanda L. Harris, Xiaohong Yang, Alex Hegmans, Lawrence F. Povirk, Susan J. Berners-Price and Nicholas P. Farrell</i>	
8.1	Introduction	191
8.2	Covalently Binding Polynuclear Platinum Complexes	192
8.3	Non-Covalent Polynuclear Platinum Complexes	193
	8.3.1 Global DNA-Binding Profile	194
	8.3.2 Solid-State Studies: A New Mode of DNA Binding	195
	8.3.3 Solution Studies: Comparison With Minor Groove Binders	196
	8.3.4 Solution Studies: Binding Location of Pre-Associated BBR3464	196
8.4	Biochemical Consequences of Non-Covalent Polynuclear Platinum Association	198
	8.4.1 Melphalan Protection Assay	198

8.4.2	Cellular Accumulation and Cellular Effects	199
8.4.3	Cytotoxicity of Non-Covalent Polynuclear Platinum Compounds	200
8.5	Conclusions	202
	Acknowledgements	202
	References	202
Chapter 9	Polyamine-Based Agents for Gene and siRNA Transfer	205
	<i>Ian S. Blagbrough, Abdelkader A. Metwally and Osama A. A. Ahmed</i>	
9.1	Introduction	205
9.2	Barriers to Polynucleotide Delivery	209
9.2.1	DNA Condensation	209
9.2.2	Cell Targeting	213
9.2.3	Cell Membrane Entry	215
9.2.4	Endosomal Escape	215
9.2.5	Nuclear Entry	216
9.2.6	Decomplexation	216
9.2.7	Transcription and Translation	217
9.3	Polyamines Used in Non-Viral Polynucleotide Formulation	217
9.3.1	Cationic Polymers	218
9.3.2	Cationic Peptides	221
9.3.3	Cationic Lipids	223
	Acknowledgments	228
	References	228
Chapter 10	The Design and Development of Polyamine-Based Analogs with Epigenetic Targets	238
	<i>Yi Huang, Laurence J. Marton and Patrick M. Woster</i>	
10.1	Polyamine–Nucleic Acid Interaction as a Potential Epigenetic Target for Cancer Therapy	238
10.2	Polyamine Analogs as HDAC Inhibitors	239
10.2.1	HDAC Inhibitors	239
10.2.2	Polyaminohydroxamic Acid (PAHA) and Polyaminobenzamide (PABA) Polyamine Derivatives as HDAC Inhibitors	240
10.3	Histone Lysine-Specific Histone Demethylase 1 (LSD1)	242
10.3.1	Discovery of LSD1	242
10.3.2	LSD1 is an Amine Oxidase Homolog	244
10.3.3	LSD1 Complex is Implicated in Tumorigenesis	245

10.4	Identification of Polyamine Analogs as LSD1 Inhibitors	245
10.4.1	Bisguanidine and Biguanide Polyamine Analogues as LSD1 Inhibitors	245
10.4.2	Oligoamine Polyamine Analogs as LSD1 Inhibitors	248
10.5	Inhibition of LSD1 by Polyamine Analogs Reactivates Aberrantly Silenced Gene Expressions in Cancer Cells	248
10.6	Polyamine Analogs Increase Activating Chromatin Marks and Decrease Repressive Marks at the Promoters of Re-Expressed Genes with Retention of DNA Hypermethylation	251
10.7	Combination of LSD1 Inhibitors with Other Agents Targeting Epigenetic Regulation of Gene Expression	251
10.8	<i>In Vivo</i> Effects of Polyamine Analogs on LSD1 and Tumor Growth	252
10.9	Conclusion	252
	Acknowledgment	253
	References	253
Chapter 11	Clinical Applications of Polyamine-Based Therapeutics	257
	<i>André S. Bachmann and Victor A. Levin</i>	
11.1	Introduction	257
11.2	Polyamine Inhibitors in Therapeutic Clinical Trials	258
11.2.1	Cancer	258
11.2.2	Other Diseases	267
11.3	Polyamine Inhibitors in Chemoprevention Trials	268
11.3.1	Cancer	268
11.4	Polyamine Analogs in Therapeutic Clinical Trials	269
11.4.1	Cancer	269
11.5	Future Directions	270
	Acknowledgments	271
	References	271
	Subject Index	277

CHAPTER 1

Polyamine Drug Discovery: Synthetic Approaches to Therapeutic Modulators of Polyamine Metabolism

PATRICK M. WOSTER*

Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, 70 President St., Charleston, SC 29425, USA

1.1 Introduction

In the following chapters, a complete description of the design, bioevaluation and development of modulators of polyamine metabolism is presented. There are numerous synthetic approaches to these inhibitors, and as such a comprehensive review of the chemical literature in this area is beyond the scope of this book. In this chapter, specific examples of synthetic approaches to nucleosides, analogs of the natural polyamines and other agents that affect polyamine metabolism are described. The reader should bear in mind that the literature is replete with alternative strategies for the synthesis of compounds described herein. However, the examples provided will allow the reader to appreciate the vast chemical diversity that is available to medicinal chemists working in the polyamine field.

RSC Drug Discovery Series No. 17

Polyamine Drug Discovery

Edited by Patrick M. Woster and Robert A. Casero, Jr.

© Royal Society of Chemistry 2012

Published by the Royal Society of Chemistry, www.rsc.org

1.2 Polyamine Metabolism as a Drug Target

The mammalian polyamine biosynthetic pathway is shown in Figure 1.1.^{1,2} Ornithine is converted to putrescine by the action of the enzyme ornithine decarboxylase (ODC). Mammalian ODC, a dimeric enzyme with a molecular weight of about 80 000, is a typical pyridoxal phosphate-requiring amino acid decarboxylase that has been studied quite extensively.³ ODC is known to be one of the control points in the polyamine biosynthetic pathway, producing a product that is committed to polyamine biosynthesis. The synthesis and degradation of ODC are controlled by a number of factors including degradation assisted by a specific ODC antizyme, a polyamine-induced protein that binds to ODC and promotes ubiquitin-independent degradation by the 26S proteasome.⁴ As a result, ODC has a functional half-life of about 10 min. Putrescine is next converted to spermidine via an aminopropyltransferase known as spermidine synthase, which requires decarboxylated *S*-adenosylmethionine as a co-substrate.⁵ A second closely related but distinct aminopropyltransferase, spermine synthase, then adds an additional aminopropyl group to spermidine to yield spermine, the longest polyamine occurring in mammalian systems.⁵ The by-product for the spermidine and spermine synthase reactions is 5'-methylthioadenosine (MTA), a potent product inhibitor for the aminopropyl transfer process.⁶ In mammalian systems, MTA is rapidly hydrolyzed by the enzyme MTA-phosphorylase, and the components are converted to adenosine and methionine *via* salvage pathways.⁷ The aminopropyl donor for both aminopropyltransferases is decarboxylated *S*-adenosylmethionine (dc-AdoMet), produced from *S*-adenosylmethionine (AdoMet) by *S*-adenosylmethionine decarboxylase (AdoMet-DC).⁸ AdoMet-DC, like ODC, is a highly regulated enzyme in mammalian cells, and also serves as a regulatory point in the pathway. However, unlike ODC, AdoMet-DC belongs to a class of pyruvyl enzymes that do not require pyridoxal phosphate as a cofactor (see below).⁹

Polyamine metabolism is tightly controlled by a combination of inducible enzymes and the import/export of cellular polyamines. In addition to the enzymes mentioned above, intracellular polyamine content is modulated by a pair of acetyltransferases. Spermidine in the cell nucleus is acetylated on the four-carbon end by spermidine-*N*⁸-acetyltransferase, possibly altering the compound's binding affinity for DNA.^{10,11} A specific deacetylase can then reverse this enzymatic acetylation. Cytoplasmic spermidine and spermine serve as substrates for spermidine/spermine-*N*¹-acetyltransferase (SSAT), resulting in acetylation on the three-carbon end of each molecule (Figure 1.1).^{5,12} The acetylated spermidine or spermine then acts as a substrate for acetylpolyamine oxidase (APAO),¹³ which catalyzes the formation of 3-acetamidopropionaldehyde and either putrescine or spermidine, respectively. Excess acetylated polyamines can also be exported from the cell via the polyamine transport system.¹⁴ More recently, a second polyamine oxidase, the inducible spermine oxidase (SMO) was discovered and characterized.^{15,16} Thus, SSAT, APAO and SMO together serve as a reverse route for the interconversion of polyamines. An additional mechanism for control of cellular polyamines is provided by the polyamine




Figure 1.1 Mammalian polyamine metabolic pathway.


transport system, which has been well characterized in some organisms (bacteria, yeast), but has not been well characterized in mammalian organisms.¹⁷ The function of enzymes in polyamine metabolism and the polyamine transport system, and the consequences of modulating their activity, are described in more detail elsewhere in this book.

1.3 Synthetic Approaches to Modulators of Polyamine Metabolism and Function

1.3.1 Ornithine Decarboxylase (ODC)

Mammalian ODC is a highly unstable protein, and cellular levels of ODC depend on rates of synthesis and degradation as outlined above. For this

reason, reversible and irreversible inhibitors of ODC have proven to be of limited value, since the synthesis of new protein occurs very rapidly in response to reduced polyamine levels in the cell. The catalytic mechanism of ODC involves the formation of a Schiff's base between the amino group of ornithine and the pyridoxal phosphate cofactor which is tightly bound to ODC. The most useful inhibitor of ODC to date, α -difluoromethylornithine (DFMO, **1**, Scheme 1.1), takes advantage of this aspect of the mechanism, and belongs to a group of rationally designed mechanism-based inactivators specifically targeted to individual amino acid decarboxylases. The chemical synthesis of DFMO is shown in Scheme 1.1.¹⁸ The (bis)benzylidene-protected amino ester **2** is treated with lithium diisopropylamide (LDA) followed by exposure to 1-chloro-2,2-difluoroethane to form the alkylated product **3**. Removal of the benzylidene protecting groups and cleavage of the methyl ester are accomplished simultaneously to afford DFMO **1** in a 60% overall yield. It is noteworthy that the pathway shown in Scheme 1.1 is not used at the industrial scale, and the large-scale production of DFMO is an expensive undertaking. Thus, until recently, the drug has been produced almost exclusively in sufficient quantities for inclusion in commercial preparations such as the lifestyle drug Vaniqa[®]. Although DFMO is available commercially in small quantities for research, the cost is prohibitive.



Scheme 1.1 Synthesis of 2,2-difluoromethylornithine (DFMO, **1**).

The mechanism of inactivation of ODC by DFMO is shown in Scheme 1.2. As a substrate analog, DFMO forms a Schiff's base with the pyridoxal phosphate cofactor bound to ODC. The subsequent decarboxylation step results in the generation of a latent electrophile, and ODC is rapidly and irreversibly deactivated by forming a covalent bond with CYS₃₆₀.¹⁹ The discovery of DFMO provided an enormous stimulus to the field of mammalian polyamine biology. Historically, DFMO has been marketed as a treatment for *Pneumocystis carinii* secondary infections in immunocompromised patients,⁵ and has been shown to be effective in curing infections of *Trypanosoma brucei gambiense* (but not *T. brucei rhodesiense*) in limited clinical trials.^{20–24}